ImmunoCellular Therapeutics to Present at the Annual Meeting of the Congress of Neurological Surgeons
October 5th, 2011
LOS ANGELES, CA – ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based therapies, today announced that John Yu, MD, Chairman, will deliver an oral presentation at the Annual Meeting of the Congress of Neurological Surgeons. The abstract titled, "A Multi-Epitope Pulsed Dendritic Cell Vaccine (ICT-107) Targeting Glioblastoma Cancer Stem Cells Reduces the Cancer Stem Cell Population in Recurrent Tumor and Is Associated with Increased Progression-free Survival," will be presented at 2:54 p.m. today in room 151B at the Washington Convention Center in Washington, D.C.
The presentation outlines immune response data and correlations of increased progression-free survival (PFS) and overall survival (OS) from the previously completed Phase I clinical trial of ICT-107. Of the 16 patients in the study, 6 showed no signs of tumor recurrence, with 3 experiencing no disease progression almost 4 years after vaccination, while the other three have exhibited PFS for at least 2.5 years. The expression of four ICT-107 antigens in the pre-vaccine tumors correlates with prolonged PFS and OS in newly diagnosed GBM patients. The decrease in tumor activity and positive antitumor cytokine responses observed in participants vs. unvaccinated patients suggest that recurrent tumors bear more chemoresistant and radioresistant cancer stem cells; and ICT-107 vaccinated patients have a decreased proportion of cancer stem cells from immunological targeting.
The poster that will accompany the oral presentation can be viewed at: http://w3.cns.org/dp/2011CNS/987.pdf
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd.
Source: ImmunoCellular Therapeutics, Ltd.